 |
8 Diseases |  |
0 Trials |
|
0 Trials |  |
14 News |  |
- |||| MK-1029 / Merck (MSD)
Trial completion, Enrollment change: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (clinicaltrials.gov) - Sep 11, 2017
P2, N=142, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=110 --> 142
- ||| MK-1029 / Merck (MSD)
Enrollment closed, Trial primary completion date: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (clinicaltrials.gov) - Jun 16, 2017
P2, N=110, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed | N=110 --> 142 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2017
- || MK-1029 / Merck (MSD)
Trial primary completion date: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (clinicaltrials.gov) - Feb 13, 2017
P2, N=110, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Sep 2017 Trial primary completion date: Sep 2017 --> Dec 2017
- |||| MK-1029 / Merck (MSD)
Enrollment open: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (clinicaltrials.gov) - May 25, 2016
P2, N=110, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2017 --> Dec 2017 Not yet recruiting --> Recruiting
- ||||| MK-1029 / Merck (MSD)
New P2 trial: Study of MK-1029 in Participants With Persistent Asthma That Cannot Be Controlled With Montelukast (MK-1029-015) (clinicaltrials.gov) - Mar 25, 2016
P2, N=110, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | MK-1029 / Merck (MSD)
Enrollment change, Trial termination, Trial primary completion date: A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012) (clinicaltrials.gov) - Aug 22, 2014
P2, N=557, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=1475 --> 557 | Recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Jun 2014
- |||| MK-1029 / Merck (MSD)
Trial completion: Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011) (clinicaltrials.gov) - May 27, 2014
P2, N=107, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=1475 --> 557 | Recruiting --> Terminated | Trial primary completion date: Jul 2016 --> Jun 2014 Active, not recruiting --> Completed
- ||| MK-1029 / Merck (MSD)
Enrollment closed: Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011) (clinicaltrials.gov) - Jan 22, 2014
P2, N=100, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| MK-1029 / Merck (MSD)
Enrollment open: A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012) (clinicaltrials.gov) - Sep 9, 2012
P2, N=1475, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||||| MK-1029 / Merck (MSD)
New P2 trial: A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012) (clinicaltrials.gov) - Aug 1, 2012
P2, N=1475, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
- ||||| MK-1029 / Merck (MSD)
New P2 trial: Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011) (clinicaltrials.gov) - Jun 19, 2012
P2, N=100, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
- MK-1029 / Merck (MSD)
Enrollment change: A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003) (clinicaltrials.gov) - Feb 8, 2012
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting --> Recruiting N=21 --> 16
- | MK-1029 / Merck (MSD)
Trial completion: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1029 in Participants With Mild to Moderate Asthma (clinicaltrials.gov) - Jan 25, 2012
P1, N=27, Completed, Sponsor: Merck Sharp & Dohme Corp.
N=21 --> 16 Active, not recruiting --> Completed
- | MK-1029 / Merck (MSD)
Trial completion: A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003) (clinicaltrials.gov) - Jan 25, 2012
P1, N=16, Completed, Sponsor: Merck Sharp & Dohme Corp.
Active, not recruiting --> Completed Recruiting --> Completed